Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants
Karen He, Ekaterina A. Khramtsova, Alfredo Cabrera‐Socorro, Yanfei Zhang, Shuwei Li, Brice A. J. Sarver, Bart Smets, Qingqin S. Li, Louis De Muynck, Antonio Parrado, Simon Lovestone, Mary Helen Black
This study examines APOE Christchurch carriers in UK Biobank to assess their risk of Alzheimer's disease, cardiovascular disease, and dyslipidemia, finding lower apoB levels and reduced AD risk.
medRxiv · Dec 5, 2022 · PreprintGenetic & Genomic Medicine